Pilot study : can inspiratory muscle training relieve symptoms ff dyspnoea and improve quality of life for advanced cancer patients ?: 1872 Board #24 June 2, 3: 30 PM - 5: 00 PM. by Lindley, Martin R. et al.
  
Pilot study : can inspiratory muscle training relieve symptoms ff
dyspnoea and improve quality of life for advanced cancer
patients ?: 1872 Board #24 June 2, 3: 30 PM - 5: 00 PM.
 
 
Item type Meetings and Proceedings
Authors Lindley, Martin R.; Faghy, Mark; Sowter, Heidi M.;
Mickleborough, Timothy D.
Citation Lindley, M. R. et al (2016) 'Pilot Study : Can Inspiratory
Muscle Training Relieve Symptoms Of Dyspnoea And
Improve Quality Of Life For Advanced Cancer Patients ?:
1872 Board #24 June 2, 3: 30 PM - 5: 00 PM.', Medicine
and Science in Sports and Exercise, 2016, 48 (5 Suppl
1):513-4
DOI 10.1249/01.mss.0000486545.72377.ea
Publisher Wolters Kluwer
Journal Medicine and Science in Sports and Exercise
Rights Archived with thanks to Medicine and science in sports and
exercise
Downloaded 13-Jan-2019 02:52:39
Link to item http://hdl.handle.net/10545/621203
 Can inspiratory muscle training relieve symptoms of dyspnoea and improve quality of 
life for advanced cancer patients? A pilot study. 
Faghy, M, A.,1,2 Lindley, M, R.,1 Sowter, H2 
1School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK 
2College of life and Natural Sciences, University of Derby, Derby, UK 
 
Background: Dyspnoea is a common symptom of advanced cancer patients, and can impact on physical, 
social and psychological wellbeing. Currently the use of opioids is recommended for people suffering with 
chronic dyspnoea, despite an association to longer term health problems. Inspiratory muscle training (IMT) 
promotes chronic adaptations within the inspiratory musculature and has consistently been shown to reduce 
dyspnoea and improve lung mechanics, functional exercise capacity and quality of life in a variety of clinical 
populations, however this has yet to be tested in patients with advanced cancer.  
Methodology: Advanced cancer patients (n=3) suffering from dyspnoea were recruited from Derby Royal 
Hospital, and consented to complete an incremental IMT programme for 9 weeks. At baseline they were given 
advice / education on breathlessness management strategies and asked to record self-set goal achievement in 
a daily diary. Functional measurements taken at baseline, and post 3 and 9 weeks included a 6 minute walk 
test (6MWT), spirometry and maximal inspiratory mouth pressure (MIP). Additionally, participants 
completed a St. Georges Respiratory Questionnaire (SGRQ) at all time points and contributed to a focus group 
at the end of the study. 
Results: We found that all participants showed a significant functional improvement after 9 weeks of IMT as 
measured by the 6MWT; although the distance travelled did not change (P >0.05), the dyspnoea and exertion 
perceived by each participant during the 6MWT was significantly reduced (P >0.05). MIP increased in two of 
the participants (by 40% and 50%), but remained the same for one participant who had a higher than predicted 
baseline MIP. During the focus group all participants asserted that this technique had helped them in their 
daily life and was easy to fit into their schedules. Encouragingly, all participants are continuing to use their 
IMT device on a maintenance programme since the end of the trial. No significant results were found with the 
SGRQ or with the goal-setting diary. 
Conclusion: IMT is a safe, effective and well-tolerated intervention for advanced cancer patients suffering 
from dyspnoea. A randomised controlled trial with a larger group of patients, and which also looks at reduction 
of opioid use as an end point, is currently being planned. 
 
 
 
